Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc.

Track LCTX — free

Use LCTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LCTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.07 +0.01 (+0.94%) At close · Aug 14
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$270.61M
Shares
252.91M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.07 Open$1.06 Day$1.05–1.09 52W close$1.02–1.96 Avg vol 30d958K Short int29.6M · 11.7% float · 26.2d Short vol39% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Oct 31, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −30%
      below
      Price vs 50-day avg −10%
      below
      RSI (14) 41
      neutral
      MACD trend Positive
      52-week position 5%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −8%
      trailing
      6-month return −40%
      trailing
      YTD return −36%
      this year
      Relative strength −53%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +36 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      11.69% of float · ▼ -1.0% MoM · 26.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      129 holders — near 3-yr high, broad support
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +53%
      Y/Y
      Gross margin 57%
      contracting
      EPS growth −211%
      Y/Y
      Free cash flow $-19.4M
      Balance sheet $40.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 60%
      annualized · 1-yr
      Max drawdown −47%
      past year
      ATR 5.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −30% Bearish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      41 Neutral
      MACD trend
      Positive Bullish
      52-week position
      5% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +36 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      11.69% of float · ▼ -1.0% MoM · 26.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      129 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 5% Range high $2
      vs 200-day avg -30% vs 50-day avg -10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      LCTX
      Lineage Cell Therapeutics, Inc.
      this stock
      		$270.61M -35.9% +53.2% — 11.7%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      129
      % held
      44.0%
      Net QoQ
      -428.3K sh
      Top holder
      BROADWOOD CAPITAL INC
      Held Float
      View
      Held by Funds
      Fund positions
      23
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      29.6M
      Days to cover
      26.2d
      Change
      -306.4K sh
      View
      Short Volume
      Short vol %
      39%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.7K
      Value
      $3.5K
      As of
      Jul 1, 2026
      View
      Off-Exchange
      Off-exchange %
      44.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $14.6M
      Net income (FY)
      $-63.5M
      EPS diluted
      $-0.28
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $96.0K
      Shares
      60.0K
      Filed
      Sep 24, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      Lineage Cell Therapeutics Reports…
      Published
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      LCTX -2.7% -7.8% -39.6% -0.9% -35.9%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.1% -12.2% -53.3% -4.9% -49.8%
      Key facts CIK 876343 CUSIP 53566P109 13F (30d) 124 filings 123 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)